Should I buy or sell Qiagen stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares. View QGEN analyst ratings or view top-rated stocks .

What is Qiagen's stock price target for 2024?

5 equities research analysts have issued 1-year target prices for Qiagen's shares. Their QGEN share price targets range from $42.00 to $60.00. On average, they predict the company's share price to reach $51.80 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts .

How have QGEN shares performed in 2023?

Qiagen's stock was trading at $49.87 at the beginning of the year. Since then, QGEN stock has decreased by 17.5% and is now trading at $41.13. View the best growth stocks for 2023 here .

When is Qiagen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024. View our QGEN earnings forecast .

How were Qiagen's earnings last quarter?

Qiagen (NYSE:QGEN) posted its quarterly earnings results on Monday, October, 30th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.01. The company earned $476 million during the quarter, compared to analysts' expectations of $469.79 million. Qiagen had a trailing twelve-month return on equity of 13.15% and a net margin of 17.01%. The business's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.53 earnings per share.

What ETFs hold Qiagen's stock?

ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM) , First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) , First Trust NYSE Arca Biotechnology Index Fund (FBT) , Newday Ocean Health ETF (AHOY) , VanEck Biotech ETF (BBH) , Franklin Genomic Advancements ETF (HELX) , WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC) .

What guidance has Qiagen issued on next quarter's earnings?

Qiagen issued an update on its FY23 earnings guidance on Monday, October, 30th. The company provided earnings per share guidance of $2.07 for the period, compared to the consensus EPS estimate of $2.06. The company issued revenue guidance of $1.97 billion, compared to the consensus revenue estimate of $1.97 billion.

What is Thierry Bernard's approval rating as Qiagen's CEO?

33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com . Thierry Bernard has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Qiagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA) , QUALCOMM (QCOM) , Gilead Sciences (GILD) , Advanced Micro Devices (AMD) , PayPal (PYPL) , Netflix (NFLX) , Pfizer (PFE) , Cisco Systems (CSCO) , Amgen (AMGN) and Lam Research (LRCX) .

Who are Qiagen's major shareholders?

Qiagen's stock is owned by many different retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (9.76%), DekaBank Deutsche Girozentrale (1.48%), Deutsche Bank AG (1.47%), Deutsche Bank AG (1.47%), Morgan Stanley (1.33%) and Legal & General Group Plc (0.89%).

How do I buy shares of Qiagen?

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Qiagen Stock Price, News & Analysis (NYSE:QGEN)

$41.13

+0.54 (+1.33%)

(As of 11/28/2023 ET)

Compare

Today's Range: $40.43
▼
$41.15
50-Day Range: $35.55
▼
$41.13
52-Week Range: $34.74
▼
$51.18

Volume: 1.50 million shs
Average Volume: 1.23 million shs
Market Capitalization: $9.38 billion

P/E Ratio: 28.37
Dividend Yield: N/A
Price Target: $51.80

Qiagen MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 25.9% Upside
$51.80 Price Target
Short Interest: Healthy
1.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.83
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 2.91%
From $2.06 to $2.12 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

357th out of 949 stocks

Biological Products, Except Diagnostic Industry

57th out of 162 stocks

3.4

Analyst's Opinion

Consensus Rating
Qiagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.80, Qiagen has a forecasted upside of 25.9% from its current price of $41.13.
Amount of Analyst Coverage
Qiagen has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.50% of the float of Qiagen has been sold short.
Short Interest Ratio / Days to Cover
Qiagen has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Qiagen has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Qiagen does not currently pay a dividend.
Dividend Growth
Qiagen does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Qiagen has received a 69.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pharmacovigilance services", "Clinical research services", and "Biochemical assay kits" products. See details.
Environmental Sustainability
The Environmental Impact score for Qiagen is -0.83.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Qiagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Qiagen insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.00% of the stock of Qiagen is held by insiders.
Percentage Held by Institutions
57.99% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Qiagen are expected to grow by 2.91% in the coming year, from $2.06 to $2.12 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Qiagen is 28.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.79.
Price to Earnings Ratio vs. Sector
The P/E ratio of Qiagen is 28.37, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 91.88.
Price to Earnings Growth Ratio
Qiagen has a PEG Ratio of 12.04. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Qiagen has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Qiagen Stock (NYSE:QGEN)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

QGEN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QGEN Stock News Headlines

November 16, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and Gain Therapeutics (GANX)

November 16, 2023 | msn.com

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 16, 2023 | finanznachrichten.de

QIAGEN N.V.: QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation

November 15, 2023 | finance.yahoo.com

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

November 9, 2023 | finance.yahoo.com

QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers

November 6, 2023 | finance.yahoo.com

QIAGEN launches complete Sample to Insight workflow for microbiome research

November 6, 2023 | finance.yahoo.com

QIAGEN's (QGEN) Molecular Diagnostics Gains Share, FX Woe Stays

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 3, 2023 | barrons.com

Qiagen N.V.

November 2, 2023 | finance.yahoo.com

QIAGEN and Element Biosciences partner to offer complete next-generation sequencing workflows for the AVITI System

November 1, 2023 | markets.businessinsider.com

Optimistic Future and Growth Potential: Key Factors for Patrick B Donnelly’s Buy Rating on Qiagen’s Stock

November 1, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Impedimed Limited (OtherIPDQF), Qiagen (QGEN) and Axonics Modulation Technologies (AXNX)

November 1, 2023 | finance.yahoo.com

Qiagen N.V. (NYSE:QGEN) Q3 2023 Earnings Call Transcript

November 1, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Buy Rating on Qiagen (QGEN)

October 31, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Beam Therapeutics (BEAM) and Iovance Biotherapeutics (IOVA)

October 31, 2023 | markets.businessinsider.com

Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends

October 31, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Qiagen (QGEN) and HCA Healthcare (HCA)

October 31, 2023 | msn.com

QIAGEN (QGEN) Q3 Earnings and Revenues Beat, Margins Down

October 31, 2023 | finanznachrichten.de

QIAGEN N.V.: QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER

October 30, 2023 | finance.yahoo.com

Qiagen (QGEN) Q3 Earnings and Revenues Surpass Estimates

October 30, 2023 | finance.yahoo.com

Qiagen (QGEN) Reports Q3 Earnings: What Key Metrics Have to Say

October 30, 2023 | sfgate.com

Qiagen: Q3 Earnings Snapshot

October 30, 2023 | finance.yahoo.com

QIAGEN exceeds outlook for Q3 2023 with 5% CER sales growth in non-COVID products and adjusted EPS of $0.50 CER

October 27, 2023 | benzinga.com

Preview: Qiagen's Earnings

October 26, 2023 | finance.yahoo.com

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

October 18, 2023 | msn.com

JP Morgan Maintains Qiagen (QGEN) Overweight Recommendation

See More Headlines

Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2023
Today: 11/28/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:QGEN
CUSIP: N/A
CIK: 1015820
Web: www.qiagen.com
Phone: (177) 355-6600
Fax: 31-77-355-6658
Employees: 6,178
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $51.80
High Stock Price Target: $60.00
Low Stock Price Target: $42.00
Potential Upside/Downside: +25.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.45
Trailing P/E Ratio: 28.37
Forward P/E Ratio: 19.97
P/E Growth: 12.13
Net Income: $423.21 million
Net Margins: 17.01%
Pretax Margin: 21.33%
Return on Equity: 13.15%
Return on Assets: 7.60%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 3.74
Quick Ratio: 2.98

Sales & Book Value

Annual Sales: $1.95 billion
Price / Sales: 4.80
Cash Flow: $3.49 per share
Price / Cash Flow: 11.79
Book Value: $15.22 per share
Price / Book: 2.70

Miscellaneous

Outstanding Shares: 228,000,000
Free Float: 207,480,000
Market Cap: $9.38 billion
Optionable: Optionable
Beta: 0.40

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Thierry Bernard (Age 58)
CEO, MD & Member of Management Board
Comp: $2.67M
Dr. Roland Sackers (Age 54)
CFO, MD & Member of Management Board
Comp: $1.33M
Mr. Antonio Santos
Senior VP & Head of Global Operations
Mr. John Gilardi
Vice President of Corporate Communications & Investor Relations
Ms. Stephany Foster (Age 44)
Senior VP & Head of Human Resources
Dr. Thomas Schweins
Senior Vice President of Life Science Business Area
Dr. Thomas Theuringer
Senior Director & Head of External Communications
Mr. Jean-Pascal Viola
Senior VP & Head of Molecular Diagnostics Business Area
Dr. Jonathan G. Sheldon Ph.D. (Age 51)
Senior Vice President of Qiagen Digital Insights Business Area
Mr. Thomas Neidert
Vice President of Global Treasury

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

QGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Qiagen stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Qiagen in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QGEN shares.
View QGEN analyst ratings or view top-rated stocks.
What is Qiagen's stock price target for 2024?: 5 equities research analysts have issued 1-year target prices for Qiagen's shares. Their QGEN share price targets range from $42.00 to $60.00. On average, they predict the company's share price to reach $51.80 in the next year. This suggests a possible upside of 25.9% from the stock's current price.
View analysts price targets for QGEN or view top-rated stocks among Wall Street analysts.
How have QGEN shares performed in 2023?: Qiagen's stock was trading at $49.87 at the beginning of the year. Since then, QGEN stock has decreased by 17.5% and is now trading at $41.13.
View the best growth stocks for 2023 here.
When is Qiagen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 6th 2024.
View our QGEN earnings forecast.
How were Qiagen's earnings last quarter?: Qiagen (NYSE:QGEN) posted its quarterly earnings results on Monday, October, 30th. The company reported $0.50 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.01. The company earned $476 million during the quarter, compared to analysts' expectations of $469.79 million. Qiagen had a trailing twelve-month return on equity of 13.15% and a net margin of 17.01%. The business's revenue was down 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.53 earnings per share.
What ETFs hold Qiagen's stock?: ETFs with the largest weight of Qiagen (NYSE:QGEN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust NYSE Arca Biotechnology Index Fund (FBT), Newday Ocean Health ETF (AHOY), VanEck Biotech ETF (BBH), Franklin Genomic Advancements ETF (HELX), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

What guidance has Qiagen issued on next quarter's earnings?: Qiagen issued an update on its FY23 earnings guidance on Monday, October, 30th. The company provided earnings per share guidance of $2.07 for the period, compared to the consensus EPS estimate of $2.06. The company issued revenue guidance of $1.97 billion, compared to the consensus revenue estimate of $1.97 billion.
What is Thierry Bernard's approval rating as Qiagen's CEO?: 33 employees have rated Qiagen Chief Executive Officer Thierry Bernard on Glassdoor.com. Thierry Bernard has an approval rating of 65% among the company's employees.
What other stocks do shareholders of Qiagen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Qiagen investors own include NVIDIA (NVDA), QUALCOMM (QCOM), Gilead Sciences (GILD), Advanced Micro Devices (AMD), PayPal (PYPL), Netflix (NFLX), Pfizer (PFE), Cisco Systems (CSCO), Amgen (AMGN) and Lam Research (LRCX).
Who are Qiagen's major shareholders?: Qiagen's stock is owned by many different retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (9.76%), DekaBank Deutsche Girozentrale (1.48%), Deutsche Bank AG (1.47%), Deutsche Bank AG (1.47%), Morgan Stanley (1.33%) and Legal & General Group Plc (0.89%).
How do I buy shares of Qiagen?: Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:QGEN) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Qiagen Stock Price, News & Analysis (NYSE:QGEN)

Qiagen MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Qiagen Stock (NYSE:QGEN)

QGEN Stock Price History

QGEN Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

QGEN Stock Analysis - Frequently Asked Questions

Overall MarketRank^™